Clinical Safety and Efficacy Issues Ariding in Relation to Alternative Formulations of nti Drugs Relevant to National Policy Development and Reimbursement Decisions - Focus on Calcineurin Inhibitors (cni).
Astellas Pharma Europe Ltd, London, UK.
N
N
Undre